A Phase 3 interventional study of 0.3% OPA-15406 and 1% OPA-15406 in Atopic Dermatitis, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2021-01-25.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing difamilast in Dermatitis, Atopic — 2 open to participants now, 2 under way, 2 of them phase 3. difamilast · Dermatitis, Atopic.
Among the 16 studies testing difamilast in Dermatitis, Atopic, this one is the 5th largest by enrollment, is one of 3 that started in 2019, is one of 10 in phase 3, and was the 8th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 16 studies testing difamilast in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 15–70
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 3 mo–14 yrs
By country, each count listing its studies:
difamilast: first FDA approval 2026 (ADQUEY). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2019.
This study's enrollment of 251 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 177 across the 16 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd.: 2 open now, 2 under way, 2 of them phase 3. Of 11 finished, 8 (73%) have results posted.
Among the 13 studies in Dermatitis, Atopic by Otsuka Holdings Co., Ltd., this one is the 4th largest by enrollment, is one of 3 that started in 2019, is one of 8 in phase 3, and was the 7th registered.
Otsuka Holdings Co., Ltd.’s Dermatitis, Atopic studies by the year they started, since 2012.
2 of the studies testing difamilast in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173478Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 2026-12 |
| NCT07184645Phase 3Otsuka Pharmaceutical Co., Ltd.A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 2027-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing difamilast in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 13 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate the superiority of the investigational medicinal product (IMP; 0.3% OPA-15406 ointment, 1% OPA-15406 ointment, or vehicle) to the vehicle when administered twice daily for 4 weeks using success rate in Investigator's Global Assessment (IGA) at Week 4 as the primary endpoint in pediatric patients with Atopic Dermatitis (AD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Twice daily
Drug: 0.3% OPA-15406
Twice daily
Drug: 1% OPA-15406
Twice daily
Drug: Placebos
Twice daily
Twice daily
Twice daily
Responder Rate of Investigator's Global Assesment (IGA) of Disease Severity
The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.
Time frame: At Week 4
Change From Baseline in Eczema Area and Severity Index (EASI) Score
The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
Time frame: Baseline, Week 4
Change From Baseline in Verbal Rating Scale (VRS) for Pruritus Score
The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
Time frame: Baseline, Week 4
| Milestone | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Started | 83 | 85 | 83 |
| Completed | 76 | 76 | 58 |
| Not completed | 7 | 9 | 25 |
| Withdrew: Adverse event | 1 | 2 | 5 |
| Withdrew: Lack of efficacy | 1 | 1 | 8 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 |
| Withdrew: Withdrawal by parent/guardian | 4 | 4 | 11 |
The investigator or subinvestigator assessed the skin symptoms using IGA. The investigator or subinvestigator scored the severity (0 = clear, 1 = almost clear, 2 =mild, 3 = moderate, 4 = severe/very severe) of the overall symptoms of the treatment area (erythema, infiltration, papules, effusion and scab formation) from baseline to Week 4. Incidence of success in IGA is defined as the rate of subjects whose IGA score is 0 (clear) or 1 (almost clear) and has improved by at least 2 grades (responders) from baseline.
| percentage of participants | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Responder Rate of Investigator's Global Assesment (IGA) of Disease Severity | 44.58 (33.66 to 55.90) | 47.06 (36.13 to 58.19) | 18.07 (10.48 to 28.05) |
The investigator or sub investigator assessed the symptoms of AD using EASI. EASI's minimum and maximum scores are 0 and 72 scores respectively. The higher the EASI score is, the more severe the symptoms of AD, and a negative change from the baseline means improvement and a positive change means worsening. The investigator or sub investigator scored the severity (0-3 points) and affected BSA (%) based on the 4 symptoms (erythema, infiltration/papules, excoriation, and lichenification) on the 4 body regions (face, neck and head ; upper limbs ;trunk; and lower limbs). Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
| score on a scale | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Change From Baseline in Eczema Area and Severity Index (EASI) Score | -4.97 ± 0.84 | -6.07 ± 0.84 | 0.35 ± 0.90 |
The investigator or subinvestigator evaluated the pruritus intensity based on VRS. The subjects aged 7 to 14 years old evaluated the pruritus intensity according to the following criteria. The subjects recorded the level of pruritus and the time and date of evaluation in a pruritus diary. 0 : None 1. : Mild 2. : Moderate 3. : Severe For subjects aged 2 to 6 years, this would not be evaluated. Number of participants analyzed represents number of participants with data at both Baseline and Week4. Participants who have no data were excluded.
| score on a scale | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| Change From Baseline in Verbal Rating Scale (VRS) for Pruritus Score | -0.80 ± 0.12 | -0.68 ± 0.12 | -0.33 ± 0.13 |
Collected over Treatment period (4 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.3% OPA-15406 | 0/83 (0%) | 0/83 (0%) | 11/83 (13.3%) |
| 1% OPA-15406 | 0/85 (0%) | 0/85 (0%) | 9/85 (10.6%) |
| Placebo | 0/83 (0%) | 0/83 (0%) | 7/83 (8.4%) |
| Event | 0.3% OPA-15406 | 1% OPA-15406 | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/83 | 7/85 | 3/83 |
| ImpetigoInfections and infestations | 6/83 | 2/85 | 5/83 |
| Age, Continuous(years) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Mean | 7.1 ± 3.3 | 7.2 ± 3.2 | 7.1 ± 2.8 | 7.1 ± 3.1 |
| Sex: Female, Male(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Female | 45 | 37 | 34 | 116 |
| Male | 38 | 48 | 49 | 135 |
| Race/Ethnicity, Customized(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Asian | 83 | 85 | 83 | 251 |
| Region of Enrollment(Participants) | 0.3% OPA-15406 | 1% OPA-15406 | Placebo | Total |
|---|---|---|---|---|
| Japan | 83 | 85 | 83 | 251 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from May 2019 to primary completion in Dec 2019, 7 months.
Results were first posted in Jan 2021, 1 year 1 month after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 7 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Difamilast
Otsuka Pharmaceutical Co., Ltd. →